The greatest benefit was observed in patients with a PD-L1 tumor proportion score (TPS) ≥ 50%, showing a median overall survival (OS) of 19.7 months [95% confidence intervals (CI): 12.1–31.4] compared to 9.7 months with chemotherapy (95% CI: 7.2–19.4; HR: 0.67, 95% CI: 0.44–1.02) (2). The gene discussed is CD274; the disease is neoplasm.